Walleye Capital
OVID icon

Walleye Capital’s Ovid Therapeutics OVID Stock Holding History

Walleye Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$984K Sell
443,362
-86,658
-16% -$155K ﹤0.01% 2088
2025
Q4 		$864K Sell
530,020
-66,697
-11% -$103K ﹤0.01% 2560
2025
Q3 		$776K Buy
+596,717
New +$517K ﹤0.01% 2290

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Walleye Capital's OVID Position: Q1 2026 in Review

Walleye Capital reduced its Ovid Therapeutics (OVID) stake by 16% in Q1 2026, selling an estimated $155K and leaving 443,362 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #2088.

Walleye Capital first reported a position in OVID in Q3 2025 and has held it in 3 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Walleye Capital held 443,362 shares of Ovid Therapeutics worth $984K as of Q1 2026.
  • Walleye Capital sold 86,658 Ovid Therapeutics shares in Q1 2026, an estimated $155K.
  • Ovid Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2088 holding.
  • Walleye Capital first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.